Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Natural killer (NK) cells have broad prospects in tumor immunotherapy due to their unique biological functions and characteristics. The introduction of chimeric antigen receptors into NK cells has been the main practical method to target NK cells to specific surface antigens so far. In contrast, T cell receptors (TCR) can recognize all cellular proteins and can provide a large number of cytotoxic T lymphocytes (CTL).
To expand its recognition ability, NK cells equipped with TCR gene delivery stand out as a novel tool in the field of adoptive immunotherapy, which can also overcome the main obstacle of "pairing error" in TCR gene therapy. At Creative Biolabs, we provide one-stop service for TCR-NK therapy development, ranging from TCR construct design and optimization, TCR virus particle packaging, TCR-NKT cell engineering, to preclinical and clinical evaluation of TCR-NK cells. We are dedicated to providing high-quality customized service to best meet your research needs, turnaround time, and budget requirements.
NK cells are the most effective cancer killer in the human body, and they can exert their effector functions without pre-stimulation. They are also not expected to express the cytokines that cause the cytokine release syndrome. Another important feature is that NK cells from one donor can be safely administered to other patients without causing graft-versus-host disease (GvHD). This provides the possibility of mass production of non-personalized cell therapy products, which can be produced in advance and can be provided on demand in an "off-the-shelf" manner.
At Creative Biolabs, we combine a wide range of TCR targets with the efficacy of allogeneic NK cells to produce transformative TCR-NK products for the treatment of solid cancers. We have a unique proprietary technology platform that involves engineered NK cells to express the selected TCR together with CD3, and CD3 constitutes a key element of signal transduction through TCR.
As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for TCR-NK therapy development, including but not limited to:
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
